Ocugen (NASDAQ:OCGN – Get Free Report)‘s stock had its “buy” rating reaffirmed by research analysts at Chardan Capital in a research note issued to investors on Thursday,Benzinga reports.
It has more than 288,000 followers on the social media platform. The active trading community monitors Stocktwits' feed, which has one million followers. Stocktwits is a real-time service that ...
Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410 ...
MALVERN, Pa., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering ...
Jan. 27, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies ...
At close: 14 November at 4:00 pm GMT-5 ...
In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Ocugen (OCGN – Research Report), with a price target of $7.00. Discover outperforming stocks ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback